Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 16/20 | 0.47 |
| ▸ | MMP3 | P08254 | 15/20 | 0.47 |
| ▸ | MMP7 | P09237 | 14/20 | 0.47 |
| ▸ | MMP13 | P45452 | 13/20 | 0.47 |
| ▸ | MMP2 | P08253 | 5/20 | 0.47 |
| ▸ | MMP9 | P14780 | 3/20 | 0.44 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7628372 | 0.94 | MMP1 (0.49) | MMP1MMP3MMP7MMP13MMP2 | |
| Hydroxyamine SCHEMBL7577224 | 0.89 | S1PR5 (0.45) | MMP1MMP3 | |
| SCHEMBL7618341 | 0.87 | MMP1 (0.50) | MMP1MMP3MMP7MMP13MMP2 | |
| SCHEMBL7505855 | 0.86 | MMP1 (0.48) | MMP1MMP3MMP7MMP13MMP2 | |
| SCHEMBL7622790 | 0.85 | MMP1 (0.53) | MMP1MMP3MMP7MMP13MMP2 | |
| SCHEMBL7650964 | 0.83 | MMP1 (0.51) | MMP1MMP3MMP7MMP13MMP2 | |
| SCHEMBL7625228 | 0.81 | MMP1 (0.44) | MMP1MMP3MMP7MMP13MMP2 | |
| SCHEMBL7643949 | 0.79 | NPSR1 (0.47) | MMP1MMP3MMP7MMP13MMP2 | |
| SCHEMBL7513095 | 0.79 | KMT2A (0.47) | MMP1MMP3MMP7MMP13MMP2 | |
| SCHEMBL7594294 | 0.79 | MMP1 (0.55) | MMP1MMP3MMP7MMP13MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6441023-B1 | FOR THERAPY OF ARTHRITIS, TUMOR METASTASIS, TISSUE ULCERATION, ABNORMAL WOUND HEALING, PERIODONTAL DISEASE, BONE DISEASE, DIABETES (INSULIN RESISTANCE) AND HIV INFECTION | AMERICAN HOME PRODUCTS CORPORATION | 2002-08-27 | — | — | US | disclosed |
| US-20020032186-A1 | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | AMERICAN CYANAMID COMPANY (US) | 2002-03-14 | — | — | US | disclosed |
| US-20020006922-A1 | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | AMERICAN CYANAMID COMPANY (US) | 2002-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032186-A1 | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | MMP12, ADAM33, MMP2 | MMP1 4/4885MMP3 12/4885MMP7 52/4885 |
| US-20020006922-A1 | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | MMP12, ADAM33, MMP2 | MMP1 7/4885MMP3 8/4885MMP7 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.